Clinical Trial Update: Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating BF-200 ALA (Ameluz) with photodynamic therapy for actinic keratosis on extremities and neck/trunk completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• BF-200 ALA (Ameluz) (amelyx? (the active is 5-ALA; brand Ameluz))

Snippet

Sponsor: Biofrontera Inc. | Conditions: Actinic Keratoses | Phase 3 | Status: COMPLETED